The ObsEva SA (NASDAQ:OBSV) stock is on the up this morning and has already gone up by 7% after the company announced that the data from the PROLONG Phase 2a proof of concept study into the product ebopiprant is going to be presented at a key event.
The product is meant for treating spontaneous preterm labour and the data is going to be presented at Virtual World Congress 2021 to be held at the Royal College of Obstetricians and Gynecologists.
The company had announced not too long ago that in the PROLONG data, the product ebopiprant had not only shown effectiveness in treating pregnant women with spontaneous preterm labour but was well tolerated by the patients as well. The data also supported the company’s decision to move on to the Phase 2b/3 stage of the adaptive study. Investors could now consider keeping an eye on the ObsEva SA stock in the coming days.
|CCI20||171.6683||Buy||Chaikin Money Flow||-0.0226||Neutral|
|MACD||-0.0094||Sell||Money Flow Index||63.2244||Buy|
|STOCH (14,3)||67.5676||Buy||STOCH RSI||1.0000||OverBought|